Human Genome Epidemiology Literature Finder
|
Records 1 - 17 (of 17 Records) |
| Query Trace: Thrombocytopenia and UGT1A1[original query] |
|---|
| A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006 Nov 1 (9): 972-8. Pillot Giancarlo A, Read William L, Hennenfent Kristin L, Marsh Sharon, Gao Feng, Viswanathan Avinash, Cummings Kristopher, McLeod Howard L, Govindan Ramaswa |
| Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008 Mar 17 (3): 695-701. Lankisch Tim O, Schulz Christoph, Zwingers Thomas, Erichsen Thomas J, Manns Michael P, Heinemann Volker, Strassburg Christian |
| Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology 2009 76 (5): 315-21. Takano Masashi, Kato Masafumi, Yoshikawa Tomoyuki, Sasaki Naoki, Hirata Junko, Furuya Kenichi, Takahashi Michiko, Yokota Harushige, Kino Nao, Horie Koji, Goto Tomoko, Fujiwara Keiichi, Ishii Kenji, Kikuchi Yoshihiro, Kita Tsuneka |
| Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC cancer 2012 12 (1): 536. Anthoney D Alan, Naik Jay, Macpherson Iain R J, Crawford Donna, Hartley John M, Hartley Janet A, Saito Tomohisa, Abe Masaichi, Jones Keith, Miwa Masanori, Twelves Christopher, Evans T R |
| Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer. Journal of cancer research and therapeutics 2014 Nov 10 Suppl C195-200. Yun Fan, Lulu Miao, Zhiyu Huang, Lei Gong, Haifeng Yu, Tao Lei, Haiyan Yang, Conghua X |
| Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study. Anticancer research 2014 Jan 34 (1): 195-201. Hirata Keiji, Nagata Naoki, Kato Takeshi, Okuyama Yusuke, Andoh Hideaki, Takahashi Kenichi, Oba Koji, Sakamoto Junichi, Hazama Shoichi, Mishima Hideyu |
| Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. Journal of clinical pharmacology 2015 Aug . Goey Andrew K L, Sissung Tristan M, Peer Cody J, Trepel Jane B, Lee Min-Jung, Tomita Yusuke, Ehrlich Sheryl, Bryla Christine, Balasubramaniam Sanjeeve, Piekarz Richard, Steinberg Seth M, Bates Susan E, Figg William |
| The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer. OncoTargets and therapy 2015 8 3575-83. Xiao Xiao-Guang, Xia Shu, Zou Man, Mei Qi, Zhou Lei, Wang Shu-Jing, Chen Yu |
| Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial. Thoracic cancer 2015 Nov 6 (6): 785-91. Shi Yuankai, Hu Yi, Hu Xingsheng, Li Xue, Lin Lin, Han Xiaoho |
| Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. British journal of cancer 2015 Feb 112 (4): 644-9. DuBois S G, Allen S, Bent M, Hilton J F, Hollinger F, Hawkins R, Courtier J, Mosse Y P, Matthay K |
| Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity. Pharmacogenomics 2016 09 17 (14): 1483-90. Bins Sander, Lenting Anne, El Bouazzaoui Samira, van Doorn Leni, Oomen-de Hoop Esther, Eskens Ferry Alm, van Schaik Ron Hn, Mathijssen Ron |
| Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6). Cancer chemotherapy and pharmacology 2017 10 80 (6): 1239-1247. Yoshino Kiyoshi, Kamiura Shoji, Yokoi Takeshi, Nakae Ruriko, Fujita Masami, Takemura Masahiko, Adachi Kazushige, Wakimoto Akinori, Nishizaki Takamichi, Shiki Yasuhiko, Tsutsui Tateki, Kanda Yuki, Kobayashi Eiji, Hashimoto Kae, Mabuchi Seiji, Ueda Yutaka, Sawada Kenjiro, Tomimatsu Takuji, Kimura Tadas |
| A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat. Cancer chemotherapy and pharmacology 2018 6 82 (3): 565-570. Peer Cody J, Hall Oliver M, Sissung Tristan M, Piekarz Richard, Balasubramaniam Sanjeeve, Bates Susan E, Figg William |
| Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer. International journal of clinical oncology 2019 Mar 24 (3): 256-261. Negoro Yutaka, Yano Ryoichi, Yoshimura Mari, Suehiro Yoko, Yamashita Shinji, Kodawara Takaaki, Watanabe Kyohei, Tsukamoto Hitoshi, Nakamura Toshiaki, Kadowaki Maiko, Morikawa Miwa, Umeda Yukihiro, Anzai Masaki, Ishizuka Tamotsu, Goto Nobuyu |
| Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. The pharmacogenomics journal 2021 Jan . Vivaldi Caterina, Crucitta Stefania, Catanese Silvia, Cucchiara Federico, Arrigoni Elena, Pecora Irene, Rofi Eleonora, Fornaro Lorenzo, Salani Francesca, Massa Valentina, Vasile Enrico, Morganti Riccardo, Danesi Romano, Del Re Marz |
| Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1. Clinical pharmacokinetics 2023 9 . Mirjam de With, Leni van Doorn, Esmay Kloet, Anne van Veggel, Maja Matic, Micha J de Neijs, Esther Oomen-de Hoop, Esther van Meerten, Ron H N van Schaik, Ron H J Mathijssen, Sander Bi |
| ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer. Pharmaceutics 2024 9 16 (9): . Andrés Barba, Laura López-Vilaró, Malena Ferre, Margarita Majem, Sergio Martinez-Recio, Olga Bell, María J Arranz, Juliana Salazar, Ivana Sulliv |
- Page last reviewed:Feb 1, 2024
- Content source: